PressDecember 18, 2024 Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia
PressDecember 17, 2024 Numinus Wellness Closes Sale of Clinics and Launches Initiative to Increase Access to Mental Health Care
PressDecember 17, 2024 Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed’s Phase IIb Palliative Care Trial
PressDecember 17, 2024 Filament Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences
PressDecember 17, 2024 MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)
PressDecember 17, 2024 Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal™ Format
PressDecember 17, 2024 Awakn Life Sciences Enters into Binding Letter of Intent for Acquisition of Awakn by Graft Polymer (UK) Plc
PressDecember 12, 2024 MindBio Announces Arrangements to Address Mailing Delays Resulting from Canada Post Strike
PressDecember 11, 2024 Awakn Announces Promising Results from Aminoindane New Chemical Entity Pre-Clinical Program
PressDecember 10, 2024 Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results
PressDecember 9, 2024 MindBio Announces Completion of Private Placement and Issuance of Listed Securities
PressDecember 9, 2024 Bionomics Publishes the Positive Results from the Phase 2 ATTUNE Study of BNC210 in Patients with Post-Traumatic Stress Disorder in NEJM Evidence
PressDecember 6, 2024 Psyence Group Enters Into Agreements With Its NASDAQ-Listed Associate, Psyence Biomedical, To Settle Outstanding Obligations
PressDecember 6, 2024 MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)
PressDecember 6, 2024 MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy
PressDecember 2, 2024 Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management
PressNovember 25, 2024 Revitalist Releases Benefits Program Giving Access To All for Ketamine Therapies Changing the Narrative of Mental Health to Risk Mitigation
PressNovember 20, 2024 Psyence Biomedical Announces Favorable Result of Nasdaq Listing Qualifications Hearing
